title: Reduced distensibility of the common carotid artery in patients treated with ergotamine.
abstract: To investigate the effect of vascular smooth muscle contraction on mechanical vessel wall properties of proximal "elastic" arteries, we investigated the effect of the vasoconstrictor ergotamine on the distensibility of the common carotid artery in 10 migraine patients with ergotamine intake, in 10 control patients with migraine headache but no prior ergotamine intake, and in 10 healthy control subjects. The patients and control subjects were matched for age, blood pressure, and sex. In the ergotamine group, 2.2 +/- 1.4 mg ergotamine tartrate (0.25 to 6 mg) was taken within 12 hours before investigation. Differences in mean 24-hour blood pressure between the study groups were excluded by 24-hour blood pressure recording and differences in arterial wall thickness by high-resolution and differences in arterial wall thickness by high-resolution B-mode ultrasound. A multigate Doppler system was used for measurement of vessel wall movements by M-mode Doppler analysis. Blood pressure was determined by sphygmomanometry. The end-diastolic diameter of the common carotid artery was insignificantly reduced in the ergotamine group compared with the healthy control subjects and control patients (healthy control subjects, 6.6 +/- 0.4 mm; control patients, 6.7 +/- 0.5 mm; patients with ergotamine intake, 6.3 +/- 0.4 mm; P = NS). Arterial distensibility was significantly lower in the patients with ergotamine intake (17.4 +/- 4.0 10(-3)/kPa) than in the healthy control subjects (22.3 +/- 5.1 10(-3)/kPa) and control patients (22.8 +/- 3.6 10(-3)/kPa) (one-way ANOVA, P = .014). The results show that ergotamine reduces the distensibility of the common carotid artery. The data suggest that vascular smooth muscle contraction can modulate the buffering function of the arterial system independently of blood pressure changes.
authors.affiliation: Department of Medicine, University of Münster, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Barenbrock
authors.forename: C
authors.initials: C
authors.lastname: Spieker
authors.forename: J
authors.initials: J
authors.lastname: Witta
authors.forename: S
authors.initials: S
authors.lastname: Evers
authors.forename: A P
authors.initials: AP
authors.lastname: Hoeks
authors.forename: K H
authors.initials: KH
authors.lastname: Rahn
authors.forename: W
authors.initials: W
authors.lastname: Zidek
mesh_terms: D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D015924:Blood Pressure Monitors; D017536:Carotid Artery, Common / Q000000981:diagnostic imaging* / Q000187:drug effects*; D003187:Compliance / Q000187:drug effects; D004878:Ergotamine / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D013997:Time Factors; D014463:Ultrasonography; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
chemical_list: D018712:Analgesics, Non-Narcotic; D014662:Vasoconstrictor Agents; D004878:Ergotamine